ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Missouri's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2003
Meetings & Education
Financial Advocacy & Patient Assistance
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
MOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves New Treatment for Hairy Cell Leukemia
On September 13, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (Lumoxiti, AstraZeneca) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.
Read the full FDA press release here
Tweets by OSSatACCC